Study of Long-Term Medical Problems and Long-Term Immunity After COVID-19 Recovery

Official Study Title: Longitudinal Study of COVID-19 Sequelae and Immunity (RECON_19)

The goals of this study are to:

1. Try and better understand any long-term medical problems experienced by people who have recovered from COVID-19;
2. Determine the type and duration of the immune response to the virus that causes COVID-19;
3. Determine if some close contacts of people with COVID-19 may have become infected with the virus, but did not develop any symptoms of COVID-19; and
4. Evaluate the mental health impact of COVID-19 in survivors.

What does the study involve?

The study will have two groups:

• People who had COVID-19 and recovered (COVID-19 group).
• People who had close contact with someone with COVID-19 but did not become infected (close contact group).

Information from the close contact group will help us determine if any medical problems or changes in laboratory tests detected in the COVID-19 group occur at a higher rate than in people who did not get COVID-19.

The study visits will occur every 6 months, and your participation in the study will end after 3 years. At the study visits, we will collect information about your health, you will have a physical examination, and a mental health assessment that may be audio-recorded. Other tests may include blood draws, chest x-ray, pulmonary function tests, and plasma collection. We plan to enroll up to 300 people in the COVID-19 group, and up to 400 people in the close contact group. Volunteers will be compensated.

Who can participate?

• You are at least 18 years old
• You had COVID-19 yourself, or you had close contact or lived in the same household with someone who had COVID-19, but you did not get symptoms yourself
• You allow the NIH to store blood and tissue samples for future research
• If female, you are not pregnant
• You are able to travel to the NIH in Bethesda, Maryland

Where is it taking place?

The NIH in Bethesda, Maryland

Visit ClinicalTrials.gov for details.